Actively Recruiting
Ga-68-CXCR4 PETCT for Detecting and Monitoring Indolent B-cell Lymphoma Evaluating Treatment Response and Risk of Aggressiveness
Led by Koo Foundation Sun Yat-Sen Cancer Center · Updated on 2024-06-14
15
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Ga-68-PentixaFor PETCT scans to detect, assess treatment response, and monitor the risk of aggressiveness in people with indolent B-cell lymphomas such as marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLLSLL, and mantle cell lymphoma. This study focuses on improving imaging accuracy compared to the current standard FDG-PET, which may not be as effective for low-grade lymphomas. The study is a phase 2 clinical trial sponsored by the Koo Foundation Sun Yat-Sen Cancer Center. Participants will undergo Ga-68-CXCR4 PETCT scans as an experimental imaging procedure to evaluate lymphoma status. This includes scans for initial staging, evaluation of therapeutic response, or follow-up examinations within 3 to 6 months for those in clinical observation. The study follows institutional lymphoma treatment principles regarding the timing of F-18-FDG PET scans. Participants must be able to lie flat for at least 30 minutes during the scan. During the study, researchers will measure how well Ga-68-CXCR4 PETCT performs in detecting and monitoring indolent B-cell lymphoma over up to 24 months, comparing it to F-18-FDG PETCT scans. They will also assess the clinical impact and prognostic value of Ga-68-CXCR4 PETCT over up to 36 months. Safety and participant health will be monitored, and informed consent is required. The overall participation period may extend up to 36 months based on outcome measurements.
CONDITIONS
Brief Title
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Research Team
Y
Yu Yi Huang, MD
C
Cheng Ling Yang, B.Rad.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here